หน้าแรก
ค้นหา
Phase 3 ALEX Study: Comparing Alecensa to Xalkori in ALK+ Lung Cancer
With Alice Tsang Shaw, MD, PhD
แสดงข้อมูลเพิ่มเติม 1
Phase 3 ALEX Study: Comparing Alecensa to Xalkori in ALK+ Lung Cancer
Phase III Results for Alectinib Compared With Crizotinib in ALK+ Metastatic NSCLC
J-Alex Trial: Should Alecensa Replace Xalkori as First-Line ALK Therapy?
Dr. Shaw on the Phase III Results of the ALEX Trial in NSCLC
Comparing Alectinib Versus Crizotinib in ALK+ NSCLC
Key findings of the ALEX study: Improved therapeutic options for ALK-positive NSCLC
Dr. Camidge on the ALEX Trial in Patients With ALK+ NSCLC
Exciting results from the ALEX trial
How Do the New ALK Inhibitor Drugs Compare to Xalkori (Crizotinib) for ALK+ Lung Cancer Patients?
Searching for new agents against lung cancer: the PROFILE 1014 and ALEX trials
Alectinib eclipses crizotnib for ALK positive lung cancer
Ceritinib and Alectinib in Relapsed ALK+ NSCLC
Alectinib in ALK-Mutated NSCLC
Alectinib for Relapsed/Refractory ALK+ NSCLC
Updates Informing the Management of ALK-rearranged mNSCLC
How to maximize clinical benefits for patients with ALK-positive non-small cell lung cancer
Promising Phase III Results for Alecensa in Early-Stage ALK-Positive Lung Cancer
Dr. Mok on Overall Survival Data From the ALEX Trial in ALK+ Lung Cancer
ALK Positive Forum Disease Progression Xalkori
ALK Positive Forum Xalkori
